Synergistic Voltaglue Adhesive Mechanisms with Alternating Electric Fields by Manisha Singh (12171)

“…Numerous improvements in electrocuring are observed with AC stimulation vs direct current, including a 35% decrease in maximum voltage, 180% improvement in kinetic rates, and 100% increase in lap-shear adhesion at 2 mA. …”

Synergistic Voltaglue Adhesive Mechanisms with Alternating Electric Fields by Manisha Singh (12171)

“…Numerous improvements in electrocuring are observed with AC stimulation vs direct current, including a 35% decrease in maximum voltage, 180% improvement in kinetic rates, and 100% increase in lap-shear adhesion at 2 mA. …”

Fitting selected WB targets into the broader network of neurodegenerative protein interactions. by Diego Iacono (10785756)

The effect of caspase-1 inhibitor on HIV-induced changes in IL-18 and IL-18BP in IEC. by Ossama Allam (5043434)

<i>Gpdh1; Ldh</i> double mutants display elevated JNK activation in the larval muscles. by Madhulika Rai (4352803)

Effects of compound 2 on histopathology of liver fibrosis. by Kun-Lin Yang (1390828)

TPM1, TPM4, PCP4 and NPY are identified as having significantly increased abundance in the hippocampus after LDR exposure. by Diego Iacono (10785756)

Pharmacological α7 nAChR activation mediates spectrin breakdown. by Justin R. King (793933)

HTRF for high-throughput screening of HCMV NEC inhibitors. by Han Chen (228557)

“…The HTRF ratio for the NEC (signal, S) was ~3-fold higher than the background (B) HTRF ratios for His-UL50 or Myc-UL53 alone (S/B ~3). Untagged UL50 decreased S/B to near background levels, serving as a positive control, while UL50_E56A, which is highly defective for UL53 binding [<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1011781#ppat.1011781.ref012" target="_blank">12</a>] did not decrease S/B, serving as a negative control. …”

Comparison of <i>Killer-Rescue</i> and split <i>ClvR</i> genetics. by Georg Oberhofer (3401438)

Genome wide effects of Rho over-production on the <i>B</i>. <i>subtilis</i> transcriptome during exponential growth and stationary phase in rich medium. by Vladimir Bidnenko (4258573)

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Gonadal development and sex ratios as a function of TL. by Frederic H. Martini (481487)

“…</p> <p>(b) Sex ratios (female:male) as a function of TL. Data were sorted into 50 mm TL intervals. …”

Morphology and long-term survival of <i>B</i>. <i>subtilis</i> Rho⁺ cells. by Vladimir Bidnenko (4258573)

Context and impact of elevated antisense expression levels in the Δ<i>rho</i> mutant. by Ulrike Mäder (205299)

“…Each annotated gene is represented by a point. There is a strong negative correlation between sense and antisense expression in the Δ<i>rho</i> mutant (Pearson correlation coefficient r = -0.73) that is also visible but much weaker in the wild-type (r = -0.30). …”

A case of retroperitoneal fibrosis responding to steroid therapy by Ryuta Watanabe (4748580)